BANGKOK, Thailand – The government announced that Thai researchers have developed and registered a domestically produced botulinum antitoxin, significantly reducing costs and enhancing national pharmaceutical security. On July 28, Deputy Government Spokesperson Ploytalay Laksameesangchan announced that the Thai Food and Drug Administration has registered TRCS BOTULINUM ANTITOXIN, a domestically developed treatment for botulism. This registration is expected to reduce the cost per dose from approximately 250,000 baht for imported products to about 25,000 baht.
This achievement will reduce Thailand’s reliance on imported medicines and further strengthen national pharmaceutical security. Botulism is a rare but potentially fatal illness that can cause muscle weakness and respiratory failure, including cases linked to contaminated canned bamboo shoots.
The antitoxin was developed through collaboration among the Thai Red Cross Society, Queen Saovabha Memorial Institute, Institute of Biological Products, National Vaccine Institute, Government Pharmaceutical Organization, and National Health Security Office. These agencies are working to include the medicine in Thailand’s healthcare benefits system.
Developed on a non-profit basis, the medicine aims to improve access to essential treatment and enhance preparedness for public health emergencies and biological threats. The deputy spokesperson stated that this achievement demonstrates Thailand’s ability to translate research into practical medical products. It also supports efforts to position Thailand as a regional antitoxin hub, contributing to public health security across the ASEAN region. (NNT)
